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Spike proteinNitric oxide is an important molecule playing a key role in a broad range of biological process such as
neurotransmission, vasodilatation and immune responses. While the anti-microbiological properties of nitric
oxide-derived reactive nitrogen intermediates (RNI) such as peroxynitrite, are known, the mechanism of
these effects are as yet poorly studied. Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) belongs
to the family Coronaviridae, was ﬁrst identiﬁed during 2002-2003. Mortality in SARS patients ranges from
between 6 to 55%. We have previously shown that nitric oxide inhibits the replication cycle of SARS-CoV in
vitro by an unknown mechanism. In this study, we have further investigated the mechanism of the inhibition
process of nitric oxide against SARS-CoV. We found that peroxynitrite, an intermediate product of nitric
oxide in solution formed by the reaction of NO with superoxide, has no effect on the replication cycle of
SARS-CoV, suggesting that the inhibition is either directly effected by NO or a derivative other than
peroxynitrite. Most interestingly, we found that NO inhibits the replication of SARS-CoV by two distinct
mechanisms. Firstly, NO or its derivatives cause a reduction in the palmitoylation of nascently expressed
spike (S) protein which affects the fusion between the S protein and its cognate receptor, angiotensin
converting enzyme 2. Secondly, NO or its derivatives cause a reduction in viral RNA production in the early
steps of viral replication, and this could possibly be due to an effect on one or both of the cysteine proteases
encoded in Orf1a of SARS-CoV.
© 2009 Elsevier Inc. All rights reserved.Introduction
Severe acute respiratory syndrome coronavirus (SARS-CoV)
belongs to the family Coronaviridae and was ﬁrst identiﬁed as a
novel coronavirus after the ﬁrst known outbreak in the fall of 2002 in
southern part of China (Resh, 2006; Tan et al., 2006). SARS-CoV is a
positive-sense RNA virus with a genome of ∼30 kb in length that
forms a distinct group within the Coronaviridae family. Common to all
known coronaviruses are the four structural proteins: spike (S),
membrane (M), envelope (E) and nucleocapsid (N) protein (Marra et
al., 2003; Rota et al., 2003). The S protein protrudes from the envelope
of the virus, which results in its characteristic crown-like appearance.
The S protein binds to speciﬁc receptors on the cell surface; in the case
of SARS-CoV, it is the angiotensin-converting enzyme 2 (ACE2). The Sd at Centre for Microbiological
ontrol, Nobels Väg 18, SE-171
ative Antiviral Research Group,
e of Molecular and Cell Biology,
. Tan), Ali.Mirazimi@smi.se
ll rights reserved.protein has two regions, S1 and S2, where S1 is involved in receptor
binding and S2 in membrane fusion (Li et al., 2005, 2006).
In order to achieve its functionality, the S protein has to undergo
numerous post-translational modiﬁcations like glycosylation (Keng et
al., 2005). In addition, Petit et al. (2007) recently showed the importance
of S-palmitoylation of the endodomain of the spike protein for the
mediation of cell fusion. Palmitoylation involves the addition of
palmitate, which is a 16-carbon saturated fatty acid, and a wide range
of proteins have been shown to carry this speciﬁc modiﬁcation (Resh,
2006). The addition of palmitate can inﬂuence the interaction between
protein and membrane, protein trafﬁcking, and protein–protein inter-
actions (Resh, 2006; Smotrys and Linder, 2004; Thorp et al., 2006). In S-
palmitoylation, the fatty acids are linked through thioester linkages to
thiol groups on cysteine residues (Greaves and Chamberlain, 2007;
Resh, 2006; Smotrys and Linder, 2004).
Nitric oxide (NO) is involved in a broad range of processes and act as
an important signalingmolecule between cells (Adler et al., 1997; Zhang
et al., 2003). NO is produced in mammalian cells by three enzymes,
neuronal (nNOS), endothelial (eNOS) and inducible nitric oxide
synthase (iNOS) and these catalyze the oxidation of L-arginine to NO
and L-citrulline (Boucher et al., 1999). Inducible nitric oxide in the host
cells is commonly elevated during infection by viruses and this can lead
to either inhibition or stimulation of viral replication (Adler et al., 1997;
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2006; Pope et al., 1998; Saxena et al., 2001; Thorp et al., 2006).
In our previous study, we showed that NO inhibits the replication
cycle of SARS-CoV (Akerstrom et al., 2005). We clearly showed that the
progeny viruses were inhibited in a concentration-dependent manner,
using the exogenous NO donor S-nitroso-N-acetyl-penicillamine
(SNAP). We also demonstrated that endogenously generated NO can
inhibit the replication cycle of SARS-CoV. Another host defence against
microbes is superoxide (O2−) which can be induced when cells are
stressed, for example during an infection (Akaike and Maeda, 2000). If
NO and O2− are elevated at the same time, theywill react rapidly to form
peroxynitrite (ONOO−), which has also been shown to have an
inhibitory effect on viruses (Akaike, 2001). Hantaviruses are one group
of viruses known to be adversely affected by peroxynitrite (Klingstrom
et al., 2006). Hence, it is unclear if the effect of NO on SARS-CoV
replication is caused by peroxynitrite or another derivative of nitric
oxide. In this studywe showthat peroxynitrite doesnot playa signiﬁcantFig. 1. SIN-1 treatment has no antiviral effect on SARS-CoV infected Vero E6 cells. Vero
E6 cells were infected with SARS-CoV at an MOI of 1.0, at 1 hpi cells were treated with
different concentrations of SIN-1 and/or MnTBAP. (A) Cells treated with different
concentrations of SIN-1. 24 hpi, virus was harvested and titers determined. (B) Cells
treated with 400 μM SIN-1 and different concentrations of MnTBAP. Virus was
harvested 24 hpi and titers determined. (C) Cells treated with different concentrations
of MnTBAP, virus was harvested 24 hpi and titers determined.
Fig. 2. Effect of SNAP on nitration and palmitoylation of S protein. Vero E6 cells were
infected with rVV-L-S at an MOI of 0.1. At 1 hpi cells were treated with 400 μM SNAP or
NAP. (A) At 24 h post-infection, the cells were lysed and immunoprecipitation was
performed with nitrotyrosine afﬁnity sorbent. Western blot was then performed using
rabbit anti-S polyclonal antibody. (B, C) At 24 h post-infection, cells were labelled with
400 μCi of [3H]-palmitic acid for 2 h, or starved with methionine-cysteine (Met-Cys)-
free medium for 30 min before being labelled with 22 μCi of [35S]-methionine-cysteine
for 2 h. The cells were then lysed and imunoprecipitation was performed with rabbit S
polyclonal antibody to detect the amount of radiolabelled S protein.role in the NO-mediated inhibition of the SARS-CoV replication cycle.
Most interestingly, our data suggest that the effect of NO or its
derivatives on the replication cycle of SARS-CoV is twofold: Firstly, NO
or its derivatives causes a reduction in the palmitoylation of the S protein
which results in the inhibition of membrane fusion mediated by the
interaction between S protein and the ACE2 receptor. Secondly, NO or its
derivatives have an inhibitory effect on the production of viral RNA,
which can be observed as early as 3 h post-infection.
Results
Peroxynitrite has no effect on SARS-CoV
SIN-1, which produces peroxynitrite, was used in conjunction with
a superoxide scavenger, MnTBAP, to determine if peroxynitrite was
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Vero E6 cells were treated with different concentrations of SIN-1, and
it was observed that no signiﬁcant inhibition of viral replication
occurred. This suggested that SIN-1 administration had no effect on
the replication cycle of SARS-CoV.
Next, we treated the SARS-CoV infected Vero E6 cells with different
concentrations of MnTBAP together with SIN-1. MnTBAP removes the
superoxide, resulting in a reduction in the amount of peroxynitrite and
an increase in the amount of free NO. The results in Fig. 1B clearly
demonstrate that with increasing amount of MnTBAP in presence of
SIN-1 (400 μM), there is an inhibition in the production of progeny virus
in a concentration-dependent manner. Although a slight reduction on
the production of progeny virus was observed when the cells were
treated with the highest concentration of MnTBAP used in this study
(800 μM, Fig. 1C), the reduction of virus replication in cells treated with
both SIN-1 and MnTBAP is signiﬁcantly higher than those treated with
MnTBAP alone. This slight reduction might be explained by the
possibility that the use of the superoxide scavengerwould have resulted
in an increase in intracellular free NO, which could then, directly or
through an intermediary compound, exert an inhibitory effect.
Treatment with NO donor leads to the nitration of the S protein of SARS-
CoV and a reduction in its palmitoylation
In order to determine whether nitric oxide or its derivatives were
reactingwith the SARS-CoV S protein, Vero E6 cells were infectedwith
recombinant vaccinia virus carrying the S gene (rVV-L-S) and treated
with 400 μM of SNAP or NAP. Following immunoprecipitation with
nitrotyrosine afﬁnity sorbent (Cayman), which speciﬁcally binds
nitrated proteins, and detection of S by Western blotting, it was
clearly demonstrated that S had been nitrated after stimulation with
SNAP but not with NAP (Fig. 2A).
To determine whether the palmitoylation of S was affected by
nitric oxide, cells infected with rVV-L-S were treated with eitherFig. 3. SNAP interferes with cell–cell membrane fusion. A 293T-GFP stable cell line was infec
trypsinized and mixed with pre-plated CHO-ACE2 cells. 6 h after mixing the cell lines, syncyt
with 400 μM SNAP (C) Infected cells, treated with 400 μM NAP (D) Mock-infected cells.SNAP, NAP, SIN-1 or SIN-1 and MnTBAP and then labelled with [3H]-
palmitic acid. After immunoprecipitation of the S protein with an
anti-S rabbit polyclonal antibody, the amount of palmitoylated S
protein detected in the SNAP-treated cells was found to be
noticeably reduced when compared to the mock-treated or NAP-
treated ones (Fig. 2B). Treatment with the peroxynitrite donor SIN-1
did not cause a reduction in the palmitoylation of S (Fig. 2C),
conﬁrming other results that showed a lack of effect by peroxynitrite
treatment on SARS-CoV titer. On the other hand, if [35S]-methionine-
cysteine labelling was used, there was no difference in the amount
of total S protein immunoprecipitated for all treatments, indicating
that the SNAP and SIN-1 treatments did not affect the expression of
S (Figs. 2B, C).
Nitric oxide reduces the cell–cell fusion activity of the S protein
An in vitro assay was used to examine the effect of nitric oxide on
the cell–cell fusion activity of the S protein (Lip et al., 2006). In this
case, the S-expressing cells were treated with SNAP or NAP before
they were mixed with CHO-ACE2 cells stably expressing the ACE2
receptor. The formation of syncytia was observed 6 h later. Cells
treated with SNAP showed no fusion (Fig. 3B), whereas cell–cell
fusion was clearly visible in the NAP (Fig. 3C) or mock-treated cells
(Fig. 3A). As expected, the mock-infected cells showed no fusion as
the S protein was not expressed (Fig. 3D).
SARS-CoV S pseudotyped virus produced in the presence of nitric oxide is
less efﬁcient in viral entry
In order to investigate the effect of SNAP on the S-mediated entry
of SARS CoV into cells, we used the HIV pseudotyped virus system to
produce pseudotyped viruses with S on the surface. Pseudotyped
viruses were produced from untreated cells or cells treated with SNAP
(200 μM or 400 μM) or NAP (200 μM or 400 μM). SNAP and NAPted with rVV-L-S and treated with SNAP or NAP 1 h post-infection. At 24 hpi cells were
ium formation was observed. (A) Infected cells, mock-treated (B) Infected cells, treated
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viruses as Western blot analysis showed that similar amounts of S
were incorporated into the pseudotyped viruses (Fig. 4A). Similar toFig. 4. SARS-CoV S pseudotyped virus produced in the presence of SNAP is less efﬁcient in v
concentrated using ultra-centrifugation through a 20% sucrose bed. (A) The presence of S an
(B) Puriﬁed viruses were used for the transduction of CHO-ACE2 cells and the degrees of vira
were computed by normalizing the entry of untreated S-bearing pseudotyped viruses to 100%
its derivatives do not exert a noticeable effect on the binding of the SARS S protein to ACE2. Ce
NAP treatment. A p24 ELISA kit was used to measure p24 concentration and concentrationour previous observation (Keng et al., 2005), two forms of S were
detected and these correspond to the unglycosylated and glycosylated
forms of the protein.iral entry. Pseudotyped viruses produced under different conditions were puriﬁed and
d HIV-1 p24 proteins in the puriﬁed viruses were determined by Western blot analysis.
l entry were determined by measuring the luciferase activities. Percentages of infectivity
. Means and standard deviation from duplicate readings were shown. (C) Nitric oxide or
lls were infected with pseudotyped virus bearing the S protein, produced under SNAP or
of bound virus was derived from a standard graph.
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expressing the S receptor ACE2 on the surface of the cells, was
reﬂected by the luciferase activity in the CHO-ACE2 cells at 72 h after
infection. As shown in Fig. 4B, the luciferase activity in the cells
infected with pseudotyped virus bearing S was signiﬁcantly higher
than those without S as the latter contained no viral envelope protein
and could not enter the CHO-ACE2 cells. The reading from the cells
infected with pseudotyped virus bearing S was normalized to 100% to
calculate percentage of infectivity. Treatment with 200 μM and
400 μM of NAP caused appropriately 15% and 25% reduction in
infectivity, respectively. However, treatment with 200 μM and 400 μM
of SNAP resulted in a signiﬁcantly higher reduction, appropriately
70%, in infectivity. In order to exclude any effect on the binding of the
S protein to the ACE2 receptor, a p24 ELISA kit (Perkin Elmer) was
used to determine the concentration of virus bound to cells infected
with the HIV pseudotyped virus which had been produced in cells
either treated with 400 μM SNAP or 400 μMNAP. As shown in Fig. 4C,
SNAP and NAP treatment had no signiﬁcant effect on the concentra-
tion of bound virus, indicating that the primary effect of SNAP
treatment on the S protein occurs post-binding, possibly during entry.
SNAP treatment reduces the production of positive-stranded viral RNA
In order to determine if the effect of nitric oxide on SARS-CoV was
limited to the post-translational modiﬁcation of the S protein, we
examined the production of viral RNA by realtime PCR analysis. RNA
isolated from SARS-CoV infected Vero E6 cells at different time points
post-infection in the presence of SNAP, NAP or mock treatment was
reverse transcribed and quantitated using primers speciﬁc for the N
gene of SARS-CoV. An identical amount of each RNA sample was also
reverse transcribed and quantitated using primers speciﬁc for GAPDH,
which served as a housekeeping control. The results showed that
SNAP treatment of Vero E6 cells resulted in a reduction in the amount
of total positive-stranded viral RNA produced. This effect was
observed as early as 3 h post-infection and viral RNA levels remained
low at 24 h post-infection (Fig. 5). In order to determine if this
observed effect could be exaggerated by pretreating Vero E6 cells with
nitric oxide, another experiment was run in parallel which included
an additional SNAP treatment step an hour before infection. The effect
observed was approximately the same as in cells treated post-Fig. 5. SNAP treatment causes a reduction in the production of positive-stranded viral
RNA. Vero E6 cells were either treated with 400 μM SNAP, NAP or mock-treated and
infected with SARS-CoV at an MOI of 1. A parallel set of cells were additionally treated
an hour before infection. Cells were harvested from all sets of treatments at 3 h and 24 h
post infection and subjected to reverse transcription and realtime PCR using primers
and probes speciﬁc for the N gene of SARS-CoV and GAPDH. Ct values obtained for N in
each sample was normalized against GAPDH control values and plotted for each time
point and treatment.infection, suggesting that the pretreatment of Vero E6 cells with nitric
oxide did not signiﬁcantly increase the effects of nitric oxide on the
production of viral RNA (Fig. 5). The possibility that the pretreatment
had an effect on SARS-CoV particles before infection was excluded by
titrating SARS-CoV that had been incubated in SNAP-containing
media, which showed that the TCID50 of the virus was unchanged
(data not shown). It has been previously shown by others that nitric
oxide or its derivatives can exert an effect on the activity of cysteine
proteases (Cao et al., 2003; Saura et al., 1999). As SARS-CoV encodes
two different cysteine proteases, PLpro and 3Cpro, we tried to
determine if the effect seen on production of positive/stranded viral
RNAmight involve a loss or reduction of the function of one or both of
these proteases, which serve to cleave the different replicase proteins
from the pp1ab polyprotein expressed from Orfs 1a and 1b of the viral
genome (Thiel et al., 2003). One simple way to study this effect would
be to look at the cleavage of replicase proteins by Western blotting. A
previously described monoclonal antibody (Kumar et al., 2007)
targeting the nsp8 protein was used against SDS-PAGE-separated
lysates from SARS-CoV infected Vero E6 cells which had been treated
with either SNAP, NAP or untreated. Surprisingly, there was no
signiﬁcant difference in nsp8 levels at 24 h post-infection (Fig. 6).
Interestingly though, two other peptide species, detected by the nsp8
antibody in infected cells, showed differences in their respective
expression levels in SNAP-treated lysates. These high molecular
weight species could possibly represent cleavage intermediates of the
ORF1a replicase polyprotein from which nsp8 is cleaved. In order to
ascertain that NO was acting in these cells, the same lysates were
probed for the SARS N protein using a monoclonal antibody against N
(Zymed Laboratories). It was observed that N expression was
signiﬁcantly reduced in the same lysates. This was consistent with
earlier work (Akerstrom et al., 2005) and showed that the SNAP
treatment was working within the Vero E6 cells.
Discussion
NOcaneither inhibit or stimulateviral replicationduringan infection
(Adler et al., 1997; Fang, 2004;Akarid et al., 1995;Akerstromet al., 2005;
Greaves and Chamberlain, 2007; Klingstrom et al., 2006; Pope et al.,
1998; Saxena et al., 2001; Thorp et al., 2006). However, there are only a
few reports demonstrating the inhibition mechanism of NO. NO has
been shown to affect Epstein–Barr virus (EBV) by downregulation of the
Zta protein, an immediate early transactivator. The downregulation of
Zta helps to maintain latency of the virus. In the same study, it was also
shown that apoptosis in B cell lines were L-arginine dependent and that
NO can inhibit apoptosis in B cells (Mannick et al., 1994). In a previous
studywehave shown that NO inhibits the replication cycle of SARS-CoV.
The administration of the exogenous NO donor, SNAP, and endogenous
cytokine inducers of NO reduced the amount of progeny virus in a
concentration-dependent manner. In tissues that are stressed or
inﬂamed, both NO and O2− are elevated. Although SNAP predominantly
increases the NO level in the cell, peroxynitrite may also become
elevated after SNAP treatment as NO can react with endogenous O2− to
form peroxynitrite. However, if SIN-1 is used instead, both NO and O2−
are produced simultaneously and peroxynitrite is rapidly formed. Our
results show that unlike SNAP, treatment of SARS-CoV infected Vero E6
cells with SIN-1 has no signiﬁcant effect on the production of progeny
virus (Fig. 1A), suggesting that peroxynitrite does not inhibit SARS-CoV
replication. Moreover, if a superoxide scavenger (MnTBAP) is used to
remove the O2− and allow more NO to accumulate inside the SIN-1-
treated cells, a signiﬁcant inhibition of the virus replication was
observed (Fig. 1B). These results clearly demonstrate that peroxynitrite
has no effect on the replication of SARS-CoV and that it is NO, or a
derivative of NO, that inhibits the virus.
Palmitoylation is an important post-translational modiﬁcation of
proteins. Petit et al. (2007) have demonstrated that palmitoylation of
the SARS-CoV S protein plays a role in S-mediated cell–cell fusion. By
Fig. 6. SNAP treatment causes a difference in observed levels of replicase polyprotein
cleavage products. Lysates from either uninfected or SARS-CoV infected Vero E6 cells
which had either been treated with SNAP, NAP or mock-treated harvested 24 h post-
infection were subjected to Western blot analysis using a monoclonal antibody
targeting the nsp8 protein.
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protein for alanines, it was shown that palmitoylation of at least two
cysteine clusters at the C-terminus was important in membrane
fusion that occurred after binding of the S protein to its cognate ACE2
receptor, critical to the infectivity of SARS-CoV. It has also been
previously shown that NO or its derivatives have an effect on the
palmitoylation of the rat myelin protein (Bizzozero et al., 2001). In
agreement with both of these ﬁndings, our results in this work
indicate that NO or its derivatives reduce the palmitoylation of the S
protein and consequently exerts an effect downstream of the S
protein binding to ACE2, which is shown by the cell–cell fusion assay.
While cell–cell fusion remains an unobserved phenomenon in SARS-
CoV infection, in this paper the cell–cell fusion assay has proved useful
in examining the interaction of the S protein and its cognate ACE2
receptor. However, the cell–cell fusion assay does not address the
question of whether the underpalmitoylation of the S protein affects
its expression, folding or incorporation into the mature virus particle.
To this end we have created a pseudotyped virus based on HIV which
incorporates the S protein and shown that SNAP treatment of cells
does not affect the expression or incorporation of the S protein and it
is only the infectivity of the pseudovirus, as shown by the luciferase
assay, that is affected. It is known that treatment of mammalian cells
with NO donors results in at least two different types of post-
translational modiﬁcations—nitration of tyrosine residues (Ischiro-
poulos et al., 1992) and S-nitrosylation of cysteine residues (Stamler
et al., 1992). We demonstrate that nitric oxide or a derivative
compound is interacting with the S protein by means of the tyrosine
nitration assay. However, as tyrosine nitration depends on the
presence of peroxynitrite (Ischiropoulos et al., 1992), which has
been excluded from having an effect on the replication cycle of SARS-
CoV in this work, this indicates that either (a) the tyrosine residues
which have been nitrated have little or no role to play in the binding
between the S protein and ACE2, or (b) that the nitration of these
tyrosine residues do not impair their role in the S-protein. The trueeffect of NO on the binding process might then manifest itself at the
cysteine residues on the S proteinwhichmayhave beenpalmitoylated,
in particular the clusters at the carboxy terminal that have been
demonstrated to play a role in cell–cell fusion. But what needs to be
determined is whether these residues have simply been under-
palmitoylated as a result of an effect on palmitoyl-acyl transferases in
the host cell or whether, given that these are cysteine residues,
competitively nitrosylated. S-nitrosylation motifs have been previ-
ously described as an acid–base motif ﬂanking cysteine residues
(Ascenzi et al., 2000, Stamler et al., 1997), and a search of the S-protein
amino acid sequence for previously described motifs yielded no
results. Further studieswill have to be done to answer these questions.
While the palmitoylation of the S protein has been shown to be
affected by the administration of SNAP as an NO donor, this is an effect
that is seen in the later steps of infection, after the expression of viral
proteins. However, nitric oxide and its derivatives have been shown in
the case of several micro-organisms to have an effect on the early
steps of replication, in both bacterial and viral infections. The work
done by several groups has demonstrated that cysteine proteases are
particularly susceptible to nitric oxide, as has been described for
coxsackieviruses (Saura et al., 1999) and adenoviruses (Cao et al.,
2003). The use of realtime PCR directed against positive-stranded RNA
species encoded by SARS-CoV showed that SNAP treatment of Vero E6
cells caused a signiﬁcant decrease in viral RNA production which
could be observed as early as 3 h post-infection compared to NAP-
treated and mock-treated controls. This observation is interesting as
SARS-CoV encodes 2 cysteine proteases, the papain-like protease
(PL2pro) and the 3C-like protease(3CLpro) (Thiel et al., 2003). These
cleave the pp1ab replicase polyprotein at non-overlapping sites to
yield 15 replicase proteins, termed nsp1 to nsp15. PL2pro is predicted
to cleave the polyprotein at 3 sites, and the rest of the non-structural
proteins have been predicted to be cleaved by 3CLpro. Hence, in order
to examine a possible effect of NO on the activity of these proteases, a
monoclonal antibody directed against the nsp8 protein was used to
look at the relative amounts of cleavage products being formed in
SARS-CoV infected Vero E6 cells treated with either SNAP, NAP or in
mock-treated cells. If NO or its derivatives exerted a discrete effect on
the activity of 3CLpro, one might expect to see a reduction in the
amount of nsp8 protein as determined by Western blotting.
Surprisingly, no difference was seen in the levels of cleaved nsp8
amongst the different treatments. However, 2 bands of higher
molecular weight (of around 60 kDa and 130 kDa) was seen to
exhibit altered intensities in SARS-CoV infected cells treated with
SNAP. As these bands are speciﬁc to infection and are detected by the
nsp8 antibody, they might represent cleavage intermediates of the
replicase polyprotein. In a 2004 study, Fan and coworkers expressed
and puriﬁed the SARS-CoV 3CLpro in order to study its activity. Using
an HPLC-based peptide cleavage assay, they found that the 11 unique
3CLpro cleavage sites on the pp1ab replicase polyprotein were cleaved
with different efﬁciencies (Fan et al., 2005). In light of this
information, the differences seen in the amounts of cleavage products
might make more sense to the observer. It could be possible that the
effect of NO or its derivatives on 3CLpro might have altered its
substrate speciﬁcities, resulting in a different pattern of cleavage
efﬁciencies from that previously observed. This might account, then,
for the lack of a difference in nsp8 levels while an accumulation is
observed for a different intermediate cleavage product which might
have had its cleavage efﬁciency altered more detrimentally. In order
to conﬁrm that NO was actually working in these samples, we
performed aWestern blot using a monoclonal antibody speciﬁc to the
N protein of SARS-CoV (Fig. 6). It was observed that the expression of
the N protein was reduced, in agreement with previous ﬁndings
(Akerstrom et al., 2005). This showed the intended effect of SNAP
treatment and therefore that the observed differences in cleavage
product intensities was being observed in cells which were being
affected by SNAP treatment.
7S. Åkerström et al. / Virology 395 (2009) 1–9From the results presented here, we suggest that the effect of nitric
oxide on the replication of SARS-CoV is at least twofold: an effect on
the production of viral RNA in the early steps of replication and a
reduction in the palmitoylation of the S protein later in the replication
cycle. What remains to be elucidated is whether both of these effects
arise strictly from a direct effect of nitric oxide or its derivatives on
viral proteins, or strictly from an effect on host factors which are
subverted in the course of infection, or a combination of both.
Materials and methods
Peroxynitrite and superoxide dismutase treatment
Vero E6 cells grown in 24-well plates were infectedwith SARS-CoV
Frankfurt strain 1 at an MOI of 1. At 1 hpi, cells were washed twice
with PBS, and medium with or without 3-morpholinosydnonimine
hydrochloride (SIN-1; Sigma-Aldrich) was added. 50, 100, 200 or
400 μM of SIN-1 were added 3 times with 4-h intervals. After 24 h, the
virus was harvested and titration of progeny virus was titrated out on
a 96-well plate containing Vero E6 cells as described previously
(Akerstrom et al., 2005). At 48 hpi, the amount of virus (TCID50) was
calculated from the cytopathic effect (CPE) induced in cell culture by
serial tenfold dilutions of the harvested virus.
Similarly, SARS-CoV infected Vero E6 cells were treated with a
superoxide scavenger, Mn(III)tetrakis(4-Benzoic acid)porphyrin
chloride (MnTBAP; Calbiochem), in the absence or presence of
400 μM SIN-1. 100, 400 or 800 μM of MnTBAP with or without
400 μM SIN-1 were added 3 times with 4-h intervals. The amount of
progeny virus was measured as described above. All SARS-CoV
infection work (described here and elsewhere in the manuscript)
was carried out at the BSL4 facility at the Swedish Institute for
Infectious Disease Control in Solna, Sweden.
Radiolabelled immunoprecipitation
Vero E6 cells grown in 60 mm dishes were infected with
recombinant vaccinia virus carrying the S gene (rVV-L-S), at a MOI
of 0.1. For mock-infected cells, a recombinant vaccinia virus carrying
the N gene (rVV-L-N) was used. Both rVV-L-S and rVV-L-N are kind
gifts from Baxter Vaccine (Orth/Donau, Austria) and have been
previously described (Lip et al., 2006). At 1 h post-infection, the cells
were treated with 400 μM of SNAP (Sigma, St. Louis, Mo.), 400 μM N-
acetylpenicillamine (NAP; Sigma), 400 μM of SIN-1 (Sigma, St. Louis,
Mo) or 400 μM of SIN-1 and 400 μM of MnTBAP (Calbiochem).
Treatments were repeated 4 times with 2-h intervals. At 24 h post-
infection, cells were labelledwith 400 μCi of [3H]-palmitic acid (Perkin
Elmer, USA) for 2 h or starved with methionine-cysteine (Met-Cys)-
free medium for 30 min before being labelled with 22 μCi of [35S]-
methionine-cysteine for 2 h. The labelled cells were washed 3 times
with cold PBS and lysed in 1 ml TES lysis buffer (20 mM Tris–HCl [pH
7.5], 100mMNaCl, 1mMEDTA, 1% Triton X-100 and 2mMPMSF). Cell
debris was removed from the lysates by centrifugation at 13,000 rpm
for 10 min. Immunoprecipitation was carried out by adding rabbit
anti-SΔ10 antibody (Keng et al., 2005) to the lysates and rotating at
4 °C for 1 h, followed by overnight incubation with protein A-
Sepharose beads (Roche Diagnostics). The beads were washed 3 times
with lysis buffer and boiled in 20 μl of 2× Laemmli's SDS loading
buffer. Samples were separated in a 7.5% SDS-PAGE gel, ﬁxed for
30 min using ﬁxing solution (10% acetic acid, 45% methanol), and
treated with Amplify Fluorographic Reagent (Amersham Biosciences)
according to protocol. Visualization was done by autoradiography.
Cell–cell membrane fusion assay
An in vitro cell fusion assay that can be used to study S-mediated
membrane fusion has been previously developed (Lip et al., 2006).Brieﬂy a 293T cell-line stably expressing GFPwas infected with rVV-L-
S in order to express the S protein and then treated with SNAP or NAP
as described above. Another stable cell line stably expressing ACE2,
CHO-ACE2, was plated in a 12-well plate in DMEM containing 1 mg/
ml porcine trypsin (JRH Biosciences Inc.). Infected 293T-GFP cells
were mixed with the CHO-ACE2 cells in a 1:1 ratio per well and
syncytium formation was observed 6 h later.
Pseudotyped virus entry assay
To produce HIV pseudotyped virus bearing the SARS-CoV S
protein, 9 μg of HIV-1 luciferase reporter vector pNL4.3.Luc.R-E-
(HIV-luc) and 4.5 μg of SARS-CoV S protein expression plasmid
(pXJ3′-S-HA) were co-transfected into 293T cells in a 100-mm dish
using Lipofectamine2000 reagent (Invitrogen) following manufac-
turer's instructions. For the negative control, the cells were trans-
fected with pNL4-3.Luc.R-E-alone. The construction of the plasmids
has been described previously (Connor et al., 1995; He et al., 1995;
Tan et al., 2004). The virus-containing medium was harvested after
72 h of incubation and centrifuged at 2000 rpm for 5 min to remove
any cell debris. Virus in the supernatant was subsequently concen-
trated through a 20% sucrose cushion for 3 h at 30,000 rpm and 4 °C by
using an SW41 rotor, and subsequently resuspended in DMEM. In
order to normalize the amount of pseudotyped virus used, 10 μl of
each sample was used to measure p24 content using a p24 ELISA kit
(Perkin Elmer), according to the manufacturer's protocol. Absorbance
readings were made at 492 nm in a plate reader (Tecan) and sample
concentrations were determined from a standard graph. Appropriate
volumes corresponding to 16 ng of pseudotyped virus were then used
to infect CHO-ACE2 cells (Chou et al., 2005). At 72 hpi, supernatant
was removed and the cells were washed and harvested in trypsin and
washed again in PBS. Cell pellet was lysed using the Promega lysis
buffer and luciferase activity was determined using a luciferase assay
kit, following manufacturer's instructions (Promega). Luciferase
readings were measured using a Veritus microplate luminometer
(Turner Biosystems).
Pseudotyped virus binding assay
HIV pseudotyped virus bearing the SARS-S protein was produced
as described in the pseudotyped virus entry assay (see above). Virus-
containing medium was harvested after 24 h of incubation and
centrifuged at 3000 rpm for 5 min to remove any cell debris. 10 μl of
themediumwere diluted 20× using DMEMand used tomeasure virus
concentration using a P24 ELISA kit (Perkin Elmer), according to the
manufacturer's protocol. Virus concentration was determined from a
standard graph, and 80 ng of virus was used for infection of CHO-ACE2
cells. CHO-ACE2 cells were pre-incubated in DMEM with 1% BSA at
4 °C for 1 h prior to infection at 4 °C for 2 h. After infection, the cells
were washed 4× using 1× PBS with 1% BSA and harvested in DMEM,
freeze–thawed six times and sonicated for 2 min with 20-s intervals.
Sampleswere centrifuged at 13,000 rpm to remove any cell debris and
200 μl of supernatant was used to determine P24 content using the
P24 ELISA kit. The concentration of bound virus was then determined
using the standard graph.
Western blot and detection of nitrated SARS-CoV S protein
Vero E6 cells grown in 60 mm dishes were infected with rVV-L-S
and rVV-L-N and treated with 400 μM SNAP or NAP as described
above. After 24 h, the cells were lysed (50 mM Tris [pH 8], 150 mM
NaCl, 0.5% NP40, 0.5% deoxycholic acid, 0.005% SDS, 1 mM PMSF) and
the concentration of total protein in the cell lysates was determined
using Coomassie Plus reagent (Pierce). Appropriate volumes yielding
500 μg of total protein from each sample were added to 20 μl of
Nitrotyrosine Afﬁnity Sorbent (Cayman Chemical) after washing the
8 S. Åkerström et al. / Virology 395 (2009) 1–9beads three times in PBS. The samples were left for rotation at 4 °C
over night. Next day, the beads were washed 3 times with lysis buffer,
resuspended in 20 μl of Laemmli's SDS loading buffer and boiled for
10 min at 100 °C. Samples were separated on a 7.5% SDS-PAGE gel,
transferred to a nitrocellulose membrane, and blocked for 1 h in room
temperature in 5% non fat dry milk in PBS with 0.1% Tween 20.
Membrane was incubated overnight in 5% non-fat dry milk with
rabbit anti-SΔ10 antibody (diluted 1:6000) at 4 °C. The next day, the
membrane was incubated with HRP-conjugated secondary antibody
(goat anti-rabbit antibody diluted 1:2000) for 1 h at room temper-
ature and washed in PBS-Tween. Detection was performed with
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Quantiﬁcation of viral RNA
Vero E6 cells were grown in 24-well plates and infected with
SARS-CoV at an MOI of 1. Cells were treated with SNAP, NAP or mock-
treated either 1 h before infection and 1 h, 3 h or 6 h post-infection or
only 1 h, 3 h, 6 h post-infection without pretreatment. At 24 h post-
infection, cells were harvested in Trizol reagent (Invitrogen) and total
RNA was extracted using an RNeasy mini kit (Qiagen). Viral RNA was
quantitated using a Nanodrop spectrophotometer and equal amounts
of total RNA were added to a reverse transcription reaction using
either of the following gene-speciﬁc primers: SARSNRTREV-5′
TTATGCCTGAGTTGAATCAGCAGAA 3′; GAPDHRTREV-5′ AGCCTTCTC-
CATGCTGGTGAAGAC 3′. Equal amounts of each reverse transcription
reaction were then added to a portion of LightCycler Taqman Master
reaction mix (Roche) along with either of the following primer pairs:
SARSNCCORFP-5′ TGCCTCTGCATTCTTTGGA 3′, SARSNCCORRP-5′-
TAAGTCAGCCATGTTCCCG 3′, GAPDHF-5′ GAAGATGGTGATGGGATTTC
3′, GAPDHR-5′ GAAGGTGAAGGTCGGAGT 3′ and the following probes:
SARSNCCORP1-5′ FAM (6-carboxy-ﬂourescein)-, TGTGACTTCCATGC-
CAATGCGTG-TAMRA (6-carboxy-tetrylrhodamine quencher) 3′ or
GAPDHP-5′FAM-,CAAGCTTCCCGTTCTCAGCC-TAMRA 3′. Cycle thresh-
old values obtained for the SARS N gene were normalized against
those for GAPDH to obtain relative quotients (2ΔΔCt) which were then
plotted for SNAP, NAP and mock treatments.
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